Tumor cells express checkpoint proteins in order to prevent an immune reaction by T-cells. Checkpoint inhibitors are successfully used in oncology to unleash a cytotoxic immune response. Unfortunately this treatment increasingly leads to immune-related adverse events which resemble various primary autoimmune disorders known in rheumatology. Potentially, checkpoint dysfunction also underlies rheumatic diseases which would open the way for new treatment options to restore immune tolerance.